Galmed Historical Income Statement
| GLMD Stock | USD 2.86 0.01 0.35% |
Historical analysis of Galmed Pharmaceuticals income statement accounts such as Selling General Administrative of 4.3 M or Other Operating Expenses of 7.1 M can show how well Galmed Pharmaceuticals performed in making a profits. Evaluating Galmed Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Galmed Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Galmed Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Galmed Pharmaceuticals is a good buy for the upcoming year.
Galmed |
About Galmed Income Statement Analysis
Galmed Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Galmed Pharmaceuticals shareholders. The income statement also shows Galmed investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Galmed Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Galmed Pharmaceuticals. It is also known as Galmed Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Galmed Pharmaceuticals income statement and is an important metric when analyzing Galmed Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Total Revenue
Total revenue comprises all receipts Galmed Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most accounts from Galmed Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Galmed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.At present, Galmed Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 7.9 M, whereas Other Operating Expenses is forecasted to decline to about 7.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 562K | 297K | 375K | 747.7K | Net Interest Income | 519K | 275K | 745K | 775.1K |
Galmed Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Galmed Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Galmed Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 171.9K | 39K | 42K | 35K | 31K | 57.1K | |
| Interest Expense | 33K | 31K | 43K | 215K | 11K | 10.5K | |
| Selling General Administrative | 4.2M | 4.1M | 5.7M | 4.7M | 3.7M | 4.3M | |
| Other Operating Expenses | 22.4M | 30.2M | 32.9M | 17.7M | 7.5M | 7.1M | |
| Operating Income | (22.4M) | (30.2M) | (32.9M) | (17.7M) | 7.5M | 7.9M | |
| Ebit | (22.5M) | (30.2M) | (32.9M) | (17.7M) | (6.9M) | (7.2M) | |
| Research Development | 18.2M | 26.1M | 27.2M | 13.0M | 3.6M | 3.4M | |
| Ebitda | (22.3M) | (30.2M) | (32.8M) | (17.6M) | (6.9M) | (7.2M) | |
| Total Operating Expenses | 22.4M | 30.2M | 32.9M | 17.7M | (7.5M) | (7.1M) | |
| Income Before Tax | (20.5M) | (28.8M) | (32.5M) | (17.9M) | (6.9M) | (7.3M) | |
| Total Other Income Expense Net | 1.9M | 1.4M | 414K | (215K) | (14.4M) | (13.7M) | |
| Net Income | (18.5M) | (27.6M) | (31.9M) | (18.6M) | (6.9M) | (7.3M) | |
| Income Tax Expense | (1.9M) | (1.2M) | (519K) | 705K | (15.0M) | (14.2M) | |
| Gross Profit | 2.0M | (35K) | (39K) | (42K) | (31K) | (29.5K) | |
| Net Income From Continuing Ops | (20.5M) | (28.8M) | (32.5M) | (17.9M) | (7.5M) | (7.9M) | |
| Net Income Applicable To Common Shares | (12.3M) | (9.9M) | (20.5M) | (28.8M) | (25.9M) | (24.6M) | |
| Net Interest Income | 1.9M | 1.2M | 519K | 275K | 745K | 775.1K | |
| Interest Income | 2.0M | 1.2M | 562K | 297K | 375K | 747.7K | |
| Reconciled Depreciation | 387K | 35K | 39K | 42K | 34K | 32.3K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.